natgillin/translations-raw huggingface dataset:
This invention also relates to a method of treating cancer, which comprises co-administering to a subject in need thereof an effective amount of a compound of Formula (I), and/or a pharmaceutically acceptable salt thereof; and at least one anti-neoplastic agent such as one selected from the group consisting of: anti-microtubule agents, plantinum coordination complexes, alkylating agents, antibiotic agents, topoisomerase II inhibitors, antimetabolites, topoisomerase I inhibitors, hormones and hormonal analogues, signal transduction pathway inhibitors, non-receptor tyrosine kinase angiogenesis inhibitors, immunotherapeutic agents, proapoptotic agents, and cell cycle signaling inhibitors. 
Spoj u skladu s patentnim zahtjevom 1 i/ili njegova farmaceutski prihvatljiva sol i najmanje jedno antineoplastično sredstvo, poput onog koje se bira iz skupine koju čine antimikrotubulska sredstva, koordinacijski kompleksi platine, alkilirajuća sredstva, antibiotska sredstva, inhibitori topoizomeraze II, antimetaboliti, inhibitori topoizomeraze I, hormoni i hormonski analozi, inhibitori puta prijenosa signala, inhibitori nereceptorskih tirozinskih kinaza kao inhibitori angiogeneze, imunoterapijska sredstva, proapoptotska sredstva, i inhibitori signala staničnog ciklusa, naznačeni time što su namijenjeni zajedničkoj primjeni u liječenju raka.
Approval by a regulatory agency is generally required for inclusion of active agents in formulations intended for human contact, and those active agents which have been or are currently approved for sunscreen use in the United States include, without limitation, para aminobenzoic acid, avobenzone, cinoxate, dioxybenzone, homosalate, menthyl anthranilate, octocrylene, octyl methoxycinnamate, octyl salicylate, oxybenzone, padimate O, phenylbenzimidazole sulfonic acid, sulisobenzone, trolamine salicylate, titanium dioxide, zinc oxide, diethanolamine methoxycinnamate, digalloy trioleate, ethyl dihydroxypropyl PABA, glyceryl aminobenzoate, lawsone with dihydroxyacetone, red petrolatum. 
Općenito se traži odobrenje od strane regulatorne agencije za uključivanje aktivnih sredstava u pripravke namijenjene za kontakt s ljudima, i ona aktivna sredstva koja su već ili se upravo odobravaju za upotrebu za zaštitu od sunca u Sjedinjenim državama uključuju, bez ograničenja, para aminobenzojevu kiselinu, avobenzon, cinoksat, dioksibenzon, homosalat, mentil antranilat, oktokrilen, oktil metoksicinamat, oktil salicilat, oksibenzon, padimat O, fenilbenzimidazol sulfonsku kiselinu, sulizobenzon, trolamin salicilat, titan dioksid, cink oksid, dietanolamin metoksicinamat, digaloj trioleat, etil dihidroksipropil PABA, gliceril aminobenzoat, lawson s dihidroksiacetonom, crveni vazelin.
chopped long glass fibres having an original length in the range from 1 to 50 mm, more preferably in the range from 1 to 10 mm, most preferably in the range from 2 to 7 mm, and 
C) sjeckana duga staklena vlakna koja imaju početnu duljinu u rasponu od 1 do 50 mm, te
The construct for the use of claim 8, wherein said administration is to be repeated at least two, three, four, five, six, seven, eight, nine of ten times, after determination of a MRD negative status. 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što navedenu primjenu treba ponoviti najmanje dva, tri, četiri, pet, šest, sedam, osam, devet ili deset puta, nakon što se odredi status negativnosti na MRD.
The results are set out in Table 5 
Rezultati su prikazani u Tabeli 5.
A method according to claim 7 or 8, wherein the vegetable oil is coconut oil, olive oil, sunflower oil and/or canola oil. 
Emulzija ulje-u-vodi prema zahtjevu 5, naznačena time da biljno ulje je kokosovo ulje, maslinovo ulje, suncokretovo ulje i/ili repičino ulje.
The electrolyzer of claim 16 wherein the anode is a titanium anode that is coated with ruthenium oxide, and wherein the cathode is an aluminum cathode. 
Elektrolizator sukladno patentnom zahtjevu 16 pri je čemu ta anoda titanijska anoda obložena s rutenij oksidom, i pri čemu je ta katoda aluminijska katoda.
subsequently firing the tile (12, 13, 14, 15; 22; 41; 50) formed from clay characterized in that the ceramic tile (12, 13, 14, 15; 22; 41; 50) comprises an opening, wherein at least one of the two zones (12, 13, 14, 15; 23, 24, 25; 51, 52) of the upper surface has a slope in the direction of the opening, and wherein the ceramic tile (12, 13, 14, 15; 22; 41; 50) is a gres porcellanato tile. 
naknadnog pečenja obložne pločice (12, 13, 14, 15; 22; 41; 50) oblikovane 1z gline, naznačena time što keramička obložna pločica (12, 13, 14, 15; 22; 41; 50) ima otvor, gdje najmanje jedno od dva područja (12, 13, 14, 15; 23, 24, 25; 51, 52) gornje površine ima nagib u smjeru otvora, te što je keramička obložna pločica (12, 13, 14, 15; 22; 41; 50) gres porcellanato obložna pločica.
A method of lowering circulating LDL levels, and/or increasing HDL/LDL ratio in an individual in need thereof comprising administering a compound according to claim 1 . 
(b) poboljšanje razina glukoze u cirkulaciji, tolerancije na glukozu i/ili cirkulacijskih razina kolesterola, snižavanje cirkulacijskih razina LDL, i/ili povećanje omjera HDL/LDL, kod pojedinca kojemu je to potrebno; ili
Eventually, the capsule 1 will even automatically fall down from the bell element 9 . FIG. 
Na kraju, čahura 1 će čak i automatski pasti dolje iz zvonastog elementa 9.
The present invention includes a compound of formula (I), and pharmaceutically acceptable salts thereof. 
PATENTNI ZAHTJEVI 1. Kombinacija spoja formule (I), ili njegove farmaceutski prihvatljive soli:
In a more preferred embodiment, it is chosen in the group including: meclofenamic acid, mefloquine, 18-B-glycyrrhetinic acid and carbenoxolone. 
Kombinacijski produkt prema patentnom zahtjevu 1, naznačeno time da je rečeno sredstvo koje blokira koneksin odabrano iz skupine koju čine: meklofenamska kiselina, 18-f-gliciretinska kiselina, meflokin te tonabersat.
The solution was evaporated and the residue dissolved in a mixture of 1:1 trifluoroethanol / methanol (140ml), and then 2-benzyloxyphenylisocynanide (9.43g) was added followed by 2-methyl-4- formyloxazole (5.0g) and the reaction stirred for 4 days at room temperature. 
Otopinu se otpari, a ostatak otopi u 1:1 smjesi trifluoretanol/metanol (140 ml), te se doda 2-benziloksifenil-izocijanid (9,43 g), zatim 2-metil-4-formiloksazol (5,0 g), a reakcijsku smjesu miješa 4 dana na sobnoj temperaturi.
Utilizing said treated water in a downstream process, wherein the water that has been treated is used as raw material in an industrial process in an open cycle. Method for treating water at low cost, according to claim 1, wherein: 
iskorištavanje navedene tretirane vode u nizvodnom industrijskom postupku (2), pri čemu se navedena tretirana voda koristi kao sirovina za industrijski postupak (2) i kruži u otvorenom ciklusu, pri čemu industrijski postupak (2) obuhvaća reverznu osmozu, desalinizaciju, kultiviranje algi, postupak akvakulture, postupak iskopavanja, i njihove kombinacije.
The acylating agent of step a) is an organic acyl halide or organic acid anhydride selected from acetic anhydride, acetyl chloride, trifluoroacetic anhydride, chloroacetic anhydride, chloro acetylchloride, dichloroacetic anhydride, trichloroacetic anhydride, benzoic anhydride, benzoyl chloride, phthalic anhydride, phtaloyl dichloride, terephthaloyldichloride, succinic anhydride, succinyl chloride, ethyl oxalyl chloride, methyl oxalyl chloride, Meldrum's acid, ethyl chloroformate, methylchloroformate, acetylsalicyloyl chloride, or any other suitable acylating agent. 
Postupak prema zahtjevu 2, naznačen time da je organski acil halid ili organski kiseli anhidrid odabran iz octenog anhidrida, acetil klorida, trifluorooctenog anhidrida, klorooctenog anhidrida, kloro acetilklorida, diklorooctenog anhidrida, triklorooctenog anhidrida, benzojevog anhidrida, benzoil klorida, ftalidnog anhidrida, ftaloil diklorida, tereftaloildiklorida, sukcinil anhidrida, sukcinil klorida, etil oksalil klorida, metil oksalil klorida, Meldrumove kiseline, etil kloroformata, metilkloroformata ili acetilsaliciloil klorida.
Magnesium Stearate 3.0 and the second layer consists of: 
.Magnezijev stearat HR P20140946 T1 a drugi sloj se sastoji od:
The use of phosphorus trichloride as solvent and reagent in the process for the preparation of [1-hydroxy-2-(3-pyridinyl)ethylidene]bisphosphonic acid and hemipentahydrate monosodium salt thereof surprisingly allows the reaction to be carried out in a homogeneous system. 
Iznenađujuće, otkriveno je da uporaba fosfor-triklorida kao otapala i reagensa u postupku priprave [1-hidroksi-2-(3- piridiniljetiliden] bisfosfonske kiseline i njene hemipentahidratne mononatrijeve soli omogućava da se reakcija provede u homogenom sustavu.
The security document according to claim 1, wherein the security feature (11) is a print layer made of a composition comprising, in the first area (11a) and in the second area (11b), a basic pigment visible in visible light. 
Zaštićeni dokument sukladno patentnom zahtjevu 1, naznačen time, što je zaštitni element (11) sloj za tiskanje je napravljen od sastava koji sadrži, u prvom području (11a) 1 u drugom području (11b), osnovni pigment vidljiv u vidljivom svjetlu.
The ball spline shaft 40 is generally hollow and tubular with a longitudinal axis 46 and a plurality of longitudinally extending grooves 64 formed in its outer surface. 
Kuglasto-klinasta osovina (40) je u principu šuplja i cjevasta, te ima više uzdužnih utora (64) na svojoj vanjskoj površini.
Embodiments of lyophilised formulations of this invention are suitable for storage at temperatures significantly higher than conventional formulation storage temperatures. 
Varijante liofiliziranih oblika ovog izuma su pogodne za čuvanje na temperaturama značajno višim od temperatura koje su uobičajene za čuvanje oblika.
A medicinal aerosol suspension formulation according to claim 1, wherein the average density of the floccules is substantially the same as the density of the propellant ± 0.2g/cm3; preferably ±0.1 g/cm3; and more preferably ± 0.05 g/cm3. 
Medicinska aerosolna suspenzijska formulacija u skladu s patentnim zahtjevom 1, naznačena time što je prosječna gustoća pahuljica ista kao gustoća pogonskog plina + 0,1 g/cm*; po mogućnosti + 0,05 g/em'.
Hal, R1 and R2 have the same meaning as in formula (VI). 
Hal, R' i R* imaju isto značenje kao u formuli (VI).
The method of claim 32, wherein the disease is systemic lupus erythematosus. 
Spoj za upotrebu prema zahtjevu 18, pri čemu je bolest sistemski lupus eritematozus.
A recombinant RhCMV or HCMV vector comprising a nucleic acid sequence encoding a heterologous antigen, wherein the heterologous antigen is a human pathogen-specific antigen isolated from human immunodeficiency virus (HIV), wherein the vector includes a deletion of one or more RhCMV or HCMV genes that are essential for or augment replication. 
Rekombinantni RhCMV ili HCMYV vektor koji sadrži sekvencu nukleinske kiseline koja kodira heterologni antigen, pri čemu heterologni antigen je ljudski patogen specifičan antigen izoliran iz virusa ljudske imunodeficijencije (HIV), naznačen time da vektor uključuje brisanje jednog 1li više gena RhCMVYV ili HCMV gena koji su esencijalni za ili povećavaju replikaciju.
EXAMPLE 3 grams of a composition of EPA and DHA ethyl esters, 76.5% assay (GC), were treated as per Example 2, through batch procedure and under slight stirring. 
Primjer 3 5 grama pripravka etil estera EPA 1 DHA, udjela 76,5 % (GC), se obrađuje kao u Primjeru 2, postupkom šarže i uz blago miješanje.
A compound selected from the group consisting (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide; and pharmaceutically acceptable salts thereof for use in the treatment of bipolar disorder. 
Spoj naznačen time da je odabran iz skupine koju čine (25)-(-)-N-(6-kloro-2,3-dihidro-benzo[1,4]dioksin-2- ilmetil)-sulfamid i njegove farmaceutski prihvatljive soli za upotrebu kod liječenja bipolarnog poremećaja.
The reaction mixture was then poured onto crushed ice and the product extracted with ether (3 x 150 ml. 
Reakcijska smjesa se tada izlije na smrvljeni led i proizvod se ekstrahira sa elerom (3x150 ml.
A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to Claim 1 wherein: ring A represents phenyl ring; ring B represents furyl, phenyl, pyrazinyl, pyridazinyl, pyridyl, pyrimidinyl or thienyl ring; 
Spoj formule (I) ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, da: prsten A predstavlja fenilni prsten; prsten B predstavlja furilni, fenilni, pirazinilni, piridazinilni, piridilni, pirimidinilni ili tenilni prsten;
with ethyl-trifluoroacetate, followed by reductive amination of protected 4-aminomethyl-piperidine with 4-formyl-tetrahydropyran and a borane and by deprotection in basic medium to yield the intermediate diamine (11) 
OLI N etil-fluoracetatom a zatim reduktivno aminiranje zaštićenog 4-aminometil-piperidina sa 4-formiltetrahidropiranom i boranom te uklanjanje zaštitne skupine u baznom mediju čime nastaje (11),
A valve gearbox as claimed in claim 10, wherein external electrical termination with said valve monitoring sensor is via terminals within said electrical compartment and without said valve having an external electrical junction box, whereby to inhibit tampering with the electrical terminations without removal of said lid. 
Sklop za upravljanje ventilom s mehaničkim prijenosom prema Zahtjevu 1, gdje se završetak vanjskih električnih veza s navedenim senzorom (83) za praćenje stanja ventila ostvaruje preko terminala koji se nalaze unutar navedenog odjeljka s električnim komponentama i bez toga da navedeni ventil (1) posjeduje vanjsku električnu razvodnu kutiju čime se sprječava neovlašteni pristup i mijenjanje električnih završetaka bez uklanjanja navedenog poklopca.
The compound of claim 23 wherein said kinase belongs to the Met, PDGFR, HER, FLK, Src, Abl, or Jak subfamilies; particularly wherein said kinase is c-Met, Ron, PDGFR beta, c-kit, EGFR, HER2, KDR, flt-3, Src, Abl, Jak1, Jak2, or Jak3 kinase; particularly wherein said kinase is c-Met. 
Metoda prema zahtjevu 54, naznačena time da navedena kinaza pripada podfamiliji Met, PDGFR, HER, FLK, Src, Abl ili Jak. Metoda prema zahtjevu 54, naznačena time da je navedena kinaza c-Met, Ron, PDGFR beta, c- kit, EGFR, HER2, KDR, flt-3, Src, Abl, Jaki, Jak2 ili Jak 3 kinaza.
A process according to claim 1 wherein during the preparation of the microcapsule or after the microcapsule formation, ammonium salts, or inorganic alkaline metal salts selected from the following ones are added: lithium chloride, sodium chloride, potassium chloride, lithium nitrate, sodium nitrate, potassium nitrate, lithium sulphate, sodium sulphate, potassium sulphate, sodium monohydrogen-phosphate, potassium monohydrogen phosphate, sodium dihydrogen-phosphate, potassium dihydrogen-phosphate; alkaline-earth metal salts selected from magnesium chloride, calcium chloride, magnesium nitrate, calcium nitrate, magnesium sulphate; and alkaline metal salts of acetic acid. 
Postupak prema zahtjevima 1-14 naznačen time da se tijekom pripremanja mikrokapsule ili nakon nastajanja mikrokapsule dodaju, soli anorganskih alkalnih metala odabrane od litijevog klorida, natrijevog klorida, kalijevog klorida, litijevog nitrata, natrijevog nitrata, kalijevog nitrata, litijevog sulfata, natrijevog sulfata, kalijevog sulfata, natrijevog monohidrogenfosfata, kalijevog monohidrogenfosfata, natrijevog dihidrogenfosfata, kalijevog dihidrogenfosfata; soli zemno alkalijskih metala odabrane od magnezijevog klorida, kalcijevog klorida, magnezijevog nitrata, kalcijevog nitrata, magnezijevog sulfata; amonijeve soli odabrane od amonijevog klorida, amonijevog sulfata, amonijevog monohidrogen fosfata, amonijevog dihidrogen fosfata; soli alkalijskih metala octene kiseline.
In other embodiments, the skin disease or disorder is a disorder of skin pigmentation. 
Farmaceutski pripravak za uporabu prema zahtjevu 32, naznačen time da je kožna bolest ili poremećaj, poremećaj pigmentacije kože.
The use according to claim 7, wherein the beta blocker is selected from the group comprising acebutolol, betaxolol, carteolol, carvedilol, labetalol, oxprenolol, penbutolol, pindolol, propranolol 
Uporaba u skladu s patentnim zahtjevom 1, naznačena time, da je beta blokator odabran iz skupine koja se sastoji od karteolola, oksprenolola, penbutolola, pindolola.
an amino terminal segment comprising a first TGFB binding domain of TGFB receptor type II, 
(a) amino terminalni segment, koji sadrži prvu TGFB-vežuću domenu receptora TGF(tip II,
For example, a higher purity can be achieved by repeating step b) and step c) of the above mentioned process if after passing step c), an insufficient purity of the N-(2-aminophenyl)-4-[N-(pyridine-3-yl)methoxycarbonylamino-methyl]-benzamide is determined. 
Postupak prema zahtjevu 2, naznačen time da se korak b) i korak c) ponavljaju ako nakon koraka c) nije dovoljno visoka čistoća N-(2-aminofenil)-4-[N-(piridin-3-il)metoksikarbonilaminometil]-benzamida.
The magnesium chloride stabilized composition of claim 5 which elicits long term storage stability as characterized by: an HIC analysis at M3 or T2 or T4 wherein the amount of the composition represented by peak 2 of the HIC chromatogram is greater than or equal to 95 wt.%; and wherein, if peak 3 is present on the HIC chromatogram, the amount of the composition represented by peak 3 is less than or equal to 3 wt.%. 
Kompozicija stabilizirana magnezij kloridom prema patentnom zahtjevu 5 koja dovodi do stabilnosti pri dugotrajnom skladištenju, naznačena: HIC analizom u M; ili T> ili Ta gdje je količina kompozicije predstavljena pikom 2 HIC kromatograma veća od, ili jednaka 95 tež.%; 1 gdje je, ukoliko je pik 3 prisutan na HIC kromatogramu, količina kompozicije predstavljena pikom 3 manja od, ili jednaka 3 tež.%.
The compound of Claim 9, where R3 is hydrogen or fluoro; R4 is hydrogen or fluoro; R5 is hydrogen or fluoro; and R6 is hydrogen, fluoro or chloro. 
Spoj u skladu s patentnim zahtjevom 9, naznačen time, da R3 je vodik ili fluoro; R4 je vodik ili fluoro; R5 je vodik ili fluoro; i R6 je vodik, fluoro ili kloro.
Aclidinium for use in a dry powder formulation according to claim 4, providing a metered nominal dose of aclidinium equivalent to from 100 to 1000 micrograms of aclidinium bromide per inhalation, preferably 200 or 400 micrograms of aclidinium bromide. 
Aklidinij za primjenu u obliku formulacije suhog praha prema zahtjevu 4, pri čemu je odmjerena nominalna doza aklidinija jednaka od 100 do 1000 mikrograma aklidinijevog bromida po inhalaciji, poželjno od 200 do 400 mikrograma aklidinijevog bromida.
The combination of claim 1 wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, colorectal carcinoma, prostate cancer, renal cell carcinoma, melanoma, hepatocellular carcinoma, cervical cancer, sarcoma, brain tumor, gastric cancer, multiple myeloma, leukemia, and lymphoma. 
Kombinacija iz patentnog zahtjeva 1, pri čemu je karcinom odabran iz grupe koja se sastoji od karcinoma dojke, karcinoma glave 1 vrata, karcinoma pluća, karcinoma jajnika, karcinoma gušterače, kolorektalnog karcinoma, karcinoma prostate, karcinoma stanica bubrega, melanoma, hepatocelularnog karcinoma, karcinoma cerviksa, sarkoma, tumora na mozgu, karcinoma želuca, multiplog mijeloma, leukemije i limfoma.
an antisense molecule, a ribozyme or a RNA interference molecule, or a small synthetic molecule antagonist of the HMGB1 interaction with RAGE or soluble RAGE (sRAGE); 
besmislenu molekulu, ribozim ili RNK-interferentnu molekulu, ili mali sintetski molekulski antagonist inteakcije HMGB1 sa RAGE, ili solubilni RAGE (sRAGE);
Analgecine for use as a medicament for the treatment of an acute ischemic cerebrovascular disease in a mammal, wherein after ischemia of brain tissue analgecine is used for decreasing the level of lactic acid in brain tissue or for increasing the activity of superoxide dismutase and wherein the acute ischemic cerebrovascular disease is selected from the group consisting of cerebral embolism, transient cerebral ischemia attack, cerebral thrombosis, cerebral arteriosclerosis, cerebral arteritis, steal syndrome of cerebral artery, cranial venous sinus and venous thrombus. 
Analgecine za uporabu kao lijek za liječenje akutne ishemijske cerebrovaskularne bolesti, gdje se nakon ishemije moždanog tkiva analgecine koristi za zaštitu živčanih stanica od ozljede ili za smanjenje razine mliječne kiseline u moždanom tkivu ili za povećanje aktivnosti superoksid dismutaze, i gdje se akutna ishemijska cerebrovaskularna bolest odabire iz skupine koju čine cerebralna embolija, tranzitna cerebralna ishemijska ataka, cerebralna tromboza, cerebralna arterioskleroza, cerebralni arteritis, sindrom krađe cerebralne arterije, kranijalni venski sinus i venski tromb.
It should be noted it could be placed in any of a variety of positions. 
Treba reći da se on može ugraditi na bilo koje od pogodnih mjesta.
wherein n is an integer from 0 to 5, and n1 is an integer from 1 to 5; 
[image] gdje je n cijeli broj od 0 do 5, a n1 je cijeli broj od 1 do 5,
the morpholinyl is optionally substituted with ═O; and 
je morfolinil, izborno supstituiran s =O; ili
A method of treating psychotic, neurological and cognitive functions diseases and disorders in a mammal, comprising administration to a subject in need therefor of a therapeutically effective amount of the compound as defined in claim 1 . 
Spoj kako je definiran u bilo kojem zahtjevu 1 do 11, naznačen time da se koristi u metodi liječenja psihotičkih, neuroloških bolesti ili poremećaja i bolesti ili poremećaja kognitivnih funkcionalnosti kod sisavaca, pri čemu navedena metoda podrazumijeva administraciju osobama u potrebi terapeutski učinkovite količine spoja kako je definiran u bilo kojem od zahtjeva 1 do 11.
A compound according to claim 1 or a salt thereof in which R1 represents an ethyl group, R2 represents a hydrogen atom and R3 represents an ethyl group. 
Spoj formule (I) u skladu s patentnim zahtjevom 1, naznačen time što R1 predstavlja etilnu skupinu, R2 predstavlja atom vodika, a R3 predstavlja etilnu skupinu; ili njegova farmaceutski prihvatljiva sol.
preblending the water soluble and/or water swellable coating material particles and substantially water insoluble polymer particles; 
1) - prvodbitno sjedinjavanje u vodi topivih materijalnih čestica, koje bubre u vodi i u vodi potpuno netopivih polimernih čestica;
Use or nanoparticles or nanoparticles' aggregates for use according to claim 10, wherein the ionizing radiations are of about 2 KeV to 1500 KeV. 
Uporaba prema zahtjevu 8, gdje su ionizirajuća zračenja od oko 2 KeV do 1500 KeV.
A process for preparing a compound of formula I-a: wherein Ring A, Ring B and Y are as defined in claim 1, 
(ta) gdje su Prsten A, Prsten B i Y definirani kao u patentnom zahtjevu 1, naznačen time što se sastoji u reduciranju spoja formule III:
The dual variable domain immunoglobulin (DVD-Ig) binding protein E26.13-SS-X3, wherein the sequences of the variable and constant regions are defined as follows: 
Imunoglobulin dvojne varijabilne domene (DVD-Ig) vezujući protein E26.13-SS-X3, naznačen time da su sekvence varijabilne i konstantne regije definirane kako slijedi:
working the cooked candy composition in a hollow rope; 
oblikovanje ukuhane bombonske mase u oblik šupljeg užeta: